Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Pacific Biosciences (PACB)

Pacific Biosciences (PACB)
1.1700 x 95 1.2000 x 31
Post-market by (Cboe BZX)
1.1700 -0.0300 (-2.50%) 04/17/25 [NASDAQ]
1.1700 x 95 1.2000 x 31
Post-market 1.1750 +0.0050 (+0.43%) 19:47 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.1600
Day High
1.2200
Open 1.2000
Previous Close 1.2000 1.2000
Volume 4,090,800 4,090,800
Avg Vol 8,736,665 8,736,665
Stochastic %K 32.52% 32.52%
Weighted Alpha -41.35 -41.35
5-Day Change -0.2100 (-15.22%) -0.2100 (-15.22%)
52-Week Range 1.0800 - 2.7200 1.0800 - 2.7200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 348,487
  • Shares Outstanding, K 297,852
  • Annual Sales, $ 154,010 K
  • Annual Income, $ -309,850 K
  • EBIT $ -272 M
  • EBITDA $ -47 M
  • 60-Month Beta 2.04
  • Price/Sales 2.32
  • Price/Cash Flow N/A
  • Price/Book 0.65

Options Overview Details

View History
  • Implied Volatility 168.76% ( -244.11%)
  • Historical Volatility 92.97%
  • IV Percentile 96%
  • IV Rank 26.55%
  • IV High 412.87% on 04/16/25
  • IV Low 80.53% on 06/03/24
  • Put/Call Vol Ratio 0.59
  • Today's Volume 524
  • Volume Avg (30-Day) 2,618
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 127,703
  • Open Int (30-Day) 118,572

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.20
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +8.33%
on 03/31/25
Period Open: 1.2400
1.4900 -21.48%
on 04/09/25
-0.0700 (-5.65%)
since 03/17/25
3-Month
1.0800 +8.33%
on 03/31/25
Period Open: 1.6400
2.0600 -43.20%
on 02/14/25
-0.4700 (-28.66%)
since 01/17/25
52-Week
1.0800 +8.33%
on 03/31/25
Period Open: 1.4000
2.7200 -56.99%
on 11/07/24
-0.2300 (-16.43%)
since 04/17/24

Most Recent Stories

More News
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks

Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks

TECH : 48.10 (-3.75%)
PACB : 1.1700 (-2.50%)
ILMN : 71.20 (-3.17%)
BRKR : 36.28 (-3.87%)
DHR : 186.83 (-2.01%)
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

TXG : 7.51 (-6.48%)
PACB : 1.1700 (-2.50%)
HIMS : 27.23 (+1.04%)
MRNA : 24.72 (-1.89%)
PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed

The company said that the decision is in response to uncertainty surrounding academic and National Institutes of Health (NIH) funding and the introduction of new tariffs under the Trump administration....

PACB : 1.1700 (-2.50%)
VTI : 258.75 (+0.21%)
IWM : 186.48 (+0.82%)
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

PACB : 1.1700 (-2.50%)
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks

Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks

TECH : 48.10 (-3.75%)
TXG : 7.51 (-6.48%)
PACB : 1.1700 (-2.50%)
BRKR : 36.28 (-3.87%)
WAT : 321.01 (-0.03%)
PacBio Grants Equity Incentive Award to New Employee

PACB : 1.1700 (-2.50%)
Jim Gibson to join PacBio as Chief Financial Officer

PACB : 1.1700 (-2.50%)
3 Reasons to Sell PACB and 1 Stock to Buy Instead

3 Reasons to Sell PACB and 1 Stock to Buy Instead

PACB : 1.1700 (-2.50%)
TTD : 50.26 (+3.74%)
Scientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

PACB : 1.1700 (-2.50%)
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

FTRE : 5.29 (+5.38%)
TECH : 48.10 (-3.75%)
PACB : 1.1700 (-2.50%)
RGEN : 130.00 (-1.59%)
MTD : 1,004.96 (-1.15%)

Business Summary

Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time...

See More

Key Turning Points

3rd Resistance Point 1.2667
2nd Resistance Point 1.2433
1st Resistance Point 1.2067
Last Price 1.1700
1st Support Level 1.1467
2nd Support Level 1.1233
3rd Support Level 1.0867

See More

52-Week High 2.7200
Fibonacci 61.8% 2.0935
Fibonacci 50% 1.9000
Fibonacci 38.2% 1.7065
Last Price 1.1700
52-Week Low 1.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro